Frascà G M, Zoumparidis N G, Borgnino L C, Neri L, Neri L, Vangelista A, Bonomini V
Institute of Nephrology, St. Orsola University Hospital, Bologna, Italy.
Int J Artif Organs. 1993 Jan;16(1):11-9.
This study reports on 9 patients suffering from Wegener's granulomatosis (WG) with crescentic GN and severe systemic manifestations. On admission the mean serum creatinine was 10.9 +/- 5.1 mg/dl (4-20 mg/dl); 8 patients were oliguric and required dialysis treatment. Renal biopsy showed crescents in all cases, involving 66 to 100% of glomeruli. Patients were treated with a protocol including: a plasma exchange (PE) course; methylprednisolone; cyclophosphamide; and an antithrombotic agent (defibrotide). Clinical picture and renal function progressively improved in all patients within the first 4 weeks of treatment. After 1 month serum creatinine was 2.7 +/- 0.8 mg/dl and dialysis was no longer needed in any patient. Five relapses occurred in 3 patients 12-26 months after the onset of the disease, while they were still receiving immunosuppressive treatment. At follow-up (22 to 112 months: mean 71) all patients were alive with no clinical signs of disease activity. One patient was on regular dialysis while the others had a serum creatinine of 1.2-2.8 mg/dl (mean 1.9). Our results confirm that crescentic GN associated with WG can be successfully treated even when associated with severe clinical picture and suggest that PE can contribute to control the disease without increasing immunosuppression.
本研究报告了9例患有韦格纳肉芽肿(WG)并伴有新月体性肾小球肾炎(GN)及严重全身表现的患者。入院时平均血清肌酐为10.9±5.1mg/dl(4 - 20mg/dl);8例患者少尿,需要透析治疗。肾活检显示所有病例均有新月体形成,累及66%至100%的肾小球。患者接受了包括以下内容的治疗方案:一个疗程的血浆置换(PE);甲泼尼龙;环磷酰胺;以及一种抗血栓药物(去纤苷)。在治疗的前4周内,所有患者的临床表现和肾功能均逐渐改善。1个月后血清肌酐为2.7±0.8mg/dl,所有患者均不再需要透析。3例患者在疾病发作12 - 26个月后仍接受免疫抑制治疗时出现了5次复发。在随访(22至112个月:平均71个月)时,所有患者均存活,无疾病活动的临床迹象。1例患者定期透析,其他患者血清肌酐为1.2 - 2.8mg/dl(平均1.9mg/dl)。我们的结果证实,即使伴有严重的临床表现,与WG相关的新月体性GN也可得到成功治疗,并表明PE有助于控制疾病,而无需增加免疫抑制。